Scientist II, Cancer Pharmacology, Translational Research

Revolution Medicines•Redwood City, CA

11d•Hybrid

About The Position

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. As a Scientist II in the Cancer Pharmacology team within the Translational Research group, in the Biomedical Discovery Research Department, you will: Contribute to advancing RAS(ON) inhibitor programs by applying cancer pharmacology and tumor biology expertise, with a focus on mechanistic understanding of RAS biology. Design, execute, and interpret in vivo efficacy and PK/PD studies (internally and via CROs) to support forward and reverse translation of RAS(ON) inhibitors Collaborate with the cross-functional quantitative modeling group, providing data, biological context, and critical evaluation to support translational PK/PD modeling (no requirement for hands-on mathematical model experience). Analyze, interpret, and communicate data clearly to internal teams and external scientific audiences. Maintain high-quality documentation, protocols, and data integrity.

Requirements

Ph.D. in pharmacology or cancer biology, or a related discipline with direct relevance to oncology drug development.
2+ years of relevant postdoc or industry experience in cancer drug discovery and development.
Solid knowledge of tumor biology and RAS signaling pathways
Demonstrated experience in designing, executing and analyzing in vivo experiments with oncology disease models.
Working knowledge of PK and PK/PD relationships, with the ability to analyze and interpret data.
Rigorous and detail-oriented with proven excellence in experimental design, data analysis, data management, and presentation.
Excellent written and verbal communication skills. Able to effectively communicate results to non-specialist and specialist audiences.
Thrives in a collaborative team setting and is driven by a desire to be innovative in a dynamic and fast-paced environment.

Nice To Haves

Familiarity with RAS biology and RAS-targeted therapies
Experience with designing and executing PKPD studies in tumor models.
An understanding of preclinical to clinical translational concepts desired.
Strong track record of research productivity as evidenced by high-quality, impactful publications.
A strong theoretical understanding of the core concepts, assumptions, and limitations associated with PK/PD mathematical modeling.

Responsibilities

Contribute to advancing RAS(ON) inhibitor programs by applying cancer pharmacology and tumor biology expertise, with a focus on mechanistic understanding of RAS biology.
Design, execute, and interpret in vivo efficacy and PK/PD studies (internally and via CROs) to support forward and reverse translation of RAS(ON) inhibitors
Collaborate with the cross-functional quantitative modeling group, providing data, biological context, and critical evaluation to support translational PK/PD modeling (no requirement for hands-on mathematical model experience).
Analyze, interpret, and communicate data clearly to internal teams and external scientific audiences.
Maintain high-quality documentation, protocols, and data integrity.